Julia Chapman

Julia Chapman serves as Senior Vice President of Corporate Strategy and Planning at Verve. Ms. Chapman is a biotech executive and advisor with a successful track record leading program, portfolio, and commercial strategy for novel therapeutic modalities. Through leadership roles at Novartis, Precision Biosciences, and BridgeBio, she has facilitated research and development of more than 20 therapies spanning vaccines, RNA medicines, cell and gene therapy, and gene-editing. Most recently, as Vice President of Business Development and Strategy at BridgeBio, she led development of AAV gene therapies for CNS, renal, and metabolic diseases, as well as partnerships to develop next-generation delivery technologies. Prior to Bridge, she led portfolio strategy and alliance management at Precision Biosciences where she supported successful Series B and IPO rounds, as well as development of partnerships with Gilead, Shire, and the University of Pennsylvania. Here, she developed in-depth knowledge of Familial Hypercholesterolemia and atherosclerotic cardiovascular disease as Precision’s portfolio included in vivo liver gene editing of PCSK9 and ANGPTL3 using meganuclease technology. Julia spent her early career at Novartis in various roles of increasing responsibility within the TechOps, Development, and Commercial Organizations and in multiple geographies, including the UK, Germany, Italy, and Switzerland. During her tenure at Novartis, her projects included Global Pandemic Planning, late-stage development of adjuvanted and quadrivalent vaccines, early-stage development of the SAM vaccine, and cross-functional M&A workstreams to support transactions with GSK and CSL. She holds a B.S.E. in Biomedical Engineering and an MBA from Duke University.